Carboprost tromethamine is a synthetic form of the hormone prostaglandin F2α, which has been used in medical practice for over four decades now. It is commonly used to induce labor, control postpartum hemorrhage and terminate pregnancy, among other uses. This article will discuss carboprost tromethamine in detail, with an emphasis on the various uses and dosages for medical professionals. In addition, it will provide information on safety concerns and potential side effects that healthcare professionals should be aware of when administering this medication to their patients.
Carboprost tromethamine is a synthetic prostaglandin analogue used to induce labor and control postpartum hemorrhage. It is sold under the brand names Hemabate and Methergine. Carboprost tromethamine has a similar structure to natural prostaglandins, which are hormones that play an important role in regulating many bodily functions, including labor and delivery. When given as an injection, carboprost tromethamine works by stimulating contractions of the uterus and increasing the production of oxytocin, a hormone that helps control bleeding after childbirth. Carboprost tromethamine is typically only used when other methods of induction or control of postpartum hemorrhage have failed.
Carboprost tromethamine is indicated for the medical termination of pregnancy through 63 days gestational age. It can also be used to control postpartum hemorrhage when uterine contractions are inadequate. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, abdominal pain and fever.
Carboprost tromethamine (Hemabate) is a prostaglandin F2-alpha analogue used to treat postpartum hemorrhage (PPH) due to uterine atony. It is administered as an intramuscular injection. The recommended dose of carboprost tromethamine for the treatment of PPH is 0.25 mg/kg administered intramuscularly every 15 minutes for two doses, followed by 0.5 mg/kg every 30 minutes for four doses, and then 1 mg/kg every 60 minutes as needed. The maximum recommended dose is 30 mg per day. For the prevention of PPH, the recommended dose of carboprost tromethamine is 0.5 mg/kg administered intramuscularly immediately after delivery of the placenta.
Carboprost tromethamine is a medication used to help induce labor or to control bleeding after childbirth or abortion. It is a synthetic version of the hormone prostaglandin F2α. Carboprost tromethamine should only be used under the supervision of a medical professional. Carboprost tromethamine should only be used under the supervision of a medical professional. It is not intended for use by pregnant women without medical supervision. This medication can cause uterine contractions. This medication can also cause side effects such as nausea, vomiting, diarrhea, abdominal pain and headache.
Carboprost tromethamine (Hemabate) is a synthetic prostaglandin used to induce labor or terminate pregnancy. It can also be used to control postpartum bleeding. Carboprost tromethamine works by causing the uterus to contract. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, headache and dizziness. This medication may also cause uterine rupture and other serious side effects in pregnant women.
Drug interactions may occur with carboprost tromethamine. The most common drug interactions include: Nonsteroidal anti-inflammatory drugs (NSAIDs), Anticoagulants (blood thinners), Aspirin, Barbiturates, Corticosteroids, Diuretics (water pills), estrogens, lithium
Carboprost Tromethamine is an important medication used to treat several medical conditions. As a medical professional, it is essential that you understand the uses, dosages and other aspects of using this drug correctly. We hope this article has provided all of the necessary information for safely administering Carboprost Tromethamine so that you can ensure your patients are receiving the best care possible.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.
2.
In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.
3.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
4.
Some low-grade prostate cancers carry higher risks than biopsy suggests
5.
Who Bears the Cost of "Forever Chemical" Cleanup?
1.
Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment
2.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
3.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
4.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
5.
Nuclear Medicine's Role in Battling Women's Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Navigating the Complexities of Ph Negative ALL - Part XVI
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation